Nothing Special   »   [go: up one dir, main page]

AR058568A1 - Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo - Google Patents

Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo

Info

Publication number
AR058568A1
AR058568A1 ARP060105627A ARP060105627A AR058568A1 AR 058568 A1 AR058568 A1 AR 058568A1 AR P060105627 A ARP060105627 A AR P060105627A AR P060105627 A ARP060105627 A AR P060105627A AR 058568 A1 AR058568 A1 AR 058568A1
Authority
AR
Argentina
Prior art keywords
ctla4
molecules
composition
initial population
mammalian cells
Prior art date
Application number
ARP060105627A
Other languages
English (en)
Inventor
Kirk J Leister
Eugene J Schaefer
Ronald Bates
David M Didio
Elizabeth A Bramhall
Robert Donaldson
Alan R Flesher
Michael Grace
Helen G Haggerty
Stephen Hosselet
David H Kirkley
Ii Reb J Russell
Richard N Schicho
David E Smolin
John M Tabor
Lee K Tay
Pallaiah Thammana
Boom Thomas Vanden
Ajoy Velayudhan
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR058568A1 publication Critical patent/AR058568A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Células de mamífero capaces de producir CTLA4-Ig recombinante y variantes de las mismas. También composiciones que comprenden CTLA4-Ig y formulaciones de las mismas. Además métodos para producir en masa CTLA4-Ig a partir de células de mamífero capaces producir esta proteína recombinante, y para purificar la CTLA4-Ig. Reivindicacion 1: Un método para la obtencion de una composicion que comprende una poblacion aislada de moléculas CTLA4-Ig a partir de un medio de cultivo líquido, el medio comprende una poblacion inicial de moléculas CTLA4-Ig, en donde (1) las moléculas CTLA4-Ig de la poblacion inicial tienen uno o más residuos de ácido siálico, (2) el numero de residuos de ácido siálico por molécula CTLA4-Ig varía dentro de la poblacion inicial, y (3) la poblacion inicial comprende el dímero CTLA4-Ig y agregados de alto peso molecular, el método caracterizado porque comprende: (a) cosechar el medio de cultivo líquido a partir de un cultivo de células de mamíferos que expresan las moléculas CTLA4-Ig; (b) separar las moléculas CTLA4-Ig de los componentes celulares; (c) separar los dímeros de CTLA4-Ig de los agregados de alto peso molecular de CTLA4-Ig; y (d) separar las moléculas CTLA4-Ig en dos o más fracciones, en donde al menos una fraccion tiene una relacion molar mayor de ácido siálico a las moléculas CTLA4-Ig comparado con al menos otra fraccion, en donde las etapas (b), (c) y (d) se llevan a cabo simultáneamente o en cualquier orden, de manera de obtener la composicion. Reivindicacion 271: Un método para inhibir una respuesta inmune en un sujeto, el método caracterizado porque comprende administrar a un sujeto que necesita del mismo una cantidad efectiva de la composicion de conformidad con cualesquiera de las reivindicaciones en combinacion con metotrexato
ARP060105627A 2005-12-20 2006-12-19 Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo AR058568A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75226705P 2005-12-20 2005-12-20
US84954306P 2006-10-05 2006-10-05

Publications (1)

Publication Number Publication Date
AR058568A1 true AR058568A1 (es) 2008-02-13

Family

ID=39059313

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105627A AR058568A1 (es) 2005-12-20 2006-12-19 Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo

Country Status (2)

Country Link
US (1) US10851150B2 (es)
AR (1) AR058568A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116659589A (zh) * 2023-07-25 2023-08-29 澳润(山东)药业有限公司 基于数据分析的阿胶糕保存环境监测方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1969007T3 (da) 2005-12-20 2013-11-25 Bristol Myers Squibb Co Sammensætninger og fremgangsmåder til fremstilling af en sammensætning
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
WO2021181415A1 (en) * 2020-03-11 2021-09-16 Dr. Reddy’S Laboratories Limited METHOD TO CONTROL SIALYLATED ISOFORMS OF AN Fc-FUSION PROTEIN
CA3234496A1 (en) * 2021-10-08 2023-04-13 Kashiv Biosciences, Llc Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography
WO2023057994A1 (en) * 2021-10-08 2023-04-13 Kashiv Biosciences, Llc Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography
CN115655776B (zh) * 2022-07-28 2023-05-23 南通大学附属医院 一种病理科样本冷冻切片系统及切片方法
CN117417427B (zh) * 2023-09-11 2024-05-07 江苏省人民医院（南京医科大学第一附属医院） 一种检测内源性自体胰岛素介导的胰岛素抗体的试剂盒
CN117314924B (zh) * 2023-11-30 2024-02-09 湖南西欧新材料有限公司 基于图像特征的电镀产品表面瑕疵检测方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4460694A (en) 1981-03-26 1984-07-17 University Of Miami Bovine glycoproteins and use in diagnosing infectious mononucleosis
US4929700A (en) 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
US5856298A (en) 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5456909A (en) 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US6084067A (en) 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
EP0722329A4 (en) 1993-09-15 1998-02-04 Alpha Therapeutic Corp CLEANING PROCESS FROM GLYCOPROTEINS ALPHA 1? ACID AND PRODUCT
US5451660A (en) 1993-12-13 1995-09-19 Genentech, Inc. Method for purifying polypeptides
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
EP0784482A2 (en) 1994-06-07 1997-07-23 The Regents Of The University Of Minnesota Methods for inhibiting antigen specific t cell responses
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
EP2275119B1 (en) 1995-07-27 2013-09-25 Genentech, Inc. Stable isotonic lyophilized protein formulation
WO1998021234A2 (en) 1996-11-15 1998-05-22 Genentech, Inc. Purification of neurotrophins
PT950067E (pt) 1996-11-27 2007-12-06 Genentech Inc Purificação por afinidade de um polipéptido numa matriz de proteína a.
ZA98533B (en) 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US20030124614A1 (en) 1997-08-29 2003-07-03 Brighams And Womens Hospital Inc. Novel T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereof
JP3394240B2 (ja) 1997-12-03 2003-04-07 ロシュ ダイアグノスティックス ゲーエムベーハー 適当にグリコシル化されたポリペプチドの製造方法
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
ES2228052T3 (es) 1998-06-01 2005-04-01 Genentech, Inc. Separacion demonomeros de anticuerpos de sus multimeros utilizando cromatografia de intercambio de iones.
US6521419B1 (en) 1998-09-22 2003-02-18 Kanakaraju Koduri Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6800457B2 (en) 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
JP4543131B2 (ja) 1999-04-26 2010-09-15 ジェネンテック， インコーポレイテッド 糖タンパク質のための細胞培養方法
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
JP5025874B2 (ja) 2000-03-27 2012-09-12 ジェネティクス インスティテュート，エルエルシー 高アニオン性タンパク質の精製方法
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
DK1248802T3 (da) 2000-05-26 2004-11-15 Bristol Myers Squibb Co Oplöselige CTLA4-mutantmolekyler og anvendelser deraf
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
MXPA02012157A (es) 2000-06-09 2003-06-06 Bristol Myers Squibb Co Metodos para regular una respuesta inmune mediada por celulas al bloquear se°ales linfociticas y al bloquear la adhesion mediada por el antigeno 1 asociado con la funcion de linfocitos.
CA2411828A1 (en) 2000-06-23 2002-01-03 Maxygen, Inc. Novel co-stimulatory molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
ES2310557T3 (es) 2000-07-03 2009-01-16 Bristol-Myers Squibb Company Procedimiento para tratar enfermedades reumaticas usando una molecula de ctla4 soluble.
US6358265B1 (en) 2000-07-18 2002-03-19 Specialized Health Products, Inc. Single-step disposable safety lancet apparatus and methods
JP2004535364A (ja) 2001-01-26 2004-11-25 エモリー・ユニバーシティ 臓器移植の免疫寛容を誘発し、異常血色素症を処置する方法
PT1397153E (pt) * 2001-05-23 2008-06-12 Bristol Myers Squibb Co Métodos para proteger um transplante alogénico de ilhéus utilizando moléculas mutantes de ctla4 solúveis
WO2003080852A1 (en) 2002-03-26 2003-10-02 Lek Pharmaceutical And Chemical Company D.D. Process for the preparation of a desired erythropoietin glyco-isoform profile
PL376821A1 (pl) 2002-03-27 2006-01-09 Immunex Corporation Sposoby zwiększania produkcji polipeptydów
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
CA2482042A1 (en) 2002-04-19 2003-10-30 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
KR100788093B1 (ko) 2002-04-26 2007-12-21 제넨테크, 인크. 단백질의 비친화성 정제
WO2004008100A2 (en) 2002-07-15 2004-01-22 Immunex Corporation Methods and media for controlling sialylation of proteins produced by mammalian cells
US6924124B1 (en) 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
MXPA05006523A (es) * 2002-12-23 2005-08-26 Squibb Bristol Myers Co Procesos de cultivo de celulas de mamiferos para la produccion de proteinas.
US7332303B2 (en) 2002-12-23 2008-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
NZ542964A (en) 2003-04-04 2008-06-30 Novartis Ag Stable, highly concentrated liquid formulations, which are particularly suitable for subcutaneous administration
CA2528551A1 (en) 2003-06-13 2005-01-13 Biogen Idec Ma Inc. Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
NZ573652A (en) 2003-08-04 2009-11-27 Bristol Myers Squibb Co Methods for treating cardiovascular disease using a soluble CTLA4 molecule
AU2004285928B2 (en) 2003-10-24 2012-02-02 Amgen, Inc. Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction
AU2004309063B2 (en) 2003-12-31 2010-10-28 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
US7253167B2 (en) 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN101584858A (zh) 2005-12-20 2009-11-25 布里斯托尔-迈尔斯斯奎布公司 稳定蛋白质制剂
DK1969007T3 (da) 2005-12-20 2013-11-25 Bristol Myers Squibb Co Sammensætninger og fremgangsmåder til fremstilling af en sammensætning
US8513393B2 (en) 2006-08-28 2013-08-20 Ares Trading S.A. Process for the purification of Fc-containing proteins
AU2007291282B2 (en) 2006-08-28 2011-10-20 Ares Trading S.A. Process for the purification of Fc-fusion proteins

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116659589A (zh) * 2023-07-25 2023-08-29 澳润(山东)药业有限公司 基于数据分析的阿胶糕保存环境监测方法
CN116659589B (zh) * 2023-07-25 2023-10-27 澳润(山东)药业有限公司 基于数据分析的阿胶糕保存环境监测方法

Also Published As

Publication number Publication date
US20190092836A1 (en) 2019-03-28
US10851150B2 (en) 2020-12-01
US20200017569A9 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
AR058568A1 (es) Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
Karlmark et al. The fractalkine receptor CX3CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes
Weiskirchen et al. Cellular and molecular functions of hepatic stellate cells in inflammatory responses and liver immunology
Alcaraz et al. Extracellular vesicles from mesenchymal stem cells as novel treatments for musculoskeletal diseases
Lievens et al. Abrogated transforming growth factor beta receptor II (TGFβRII) signalling in dendritic cells promotes immune reactivity of T cells resulting in enhanced atherosclerosis
Matsuoka et al. High-mobility group box 1 is involved in the initial events of early loss of transplanted islets in mice
Elzey et al. The emerging role of platelets in adaptive immunity
Chiarini et al. Danger-sensing/patten recognition receptors and neuroinflammation in Alzheimer’s disease
US7959908B2 (en) Methods of treating viral infections using IL-21
TW201718002A (zh) 用於治療血源癌症之免疫查核點抑制劑
CY1114887T1 (el) Συνθεσεις και μεθοδοι παρασκευης συνθεσης
BRPI0606867A2 (pt) formulação lìquida; forma de dosagem unitária farmacêutica; kit; recipiente; método para aumentar a estabilidade de um polipeptìdeo de ligação a antìgeno numa formulação; método para preparar uma forma de dosagem unitária farmacêutica; formulação estável; formulação; e produto terapêutico
AR072897A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
KR20170005801A (ko) 면역조절을 위한 방법 및 조성물
US20130052198A1 (en) Anti-inflammatory factors
Parente et al. The long pentraxin PTX3 in bone homeostasis and pathology
EA201001044A1 (ru) Умами-активная фракция и способ её приготовления
Pievani et al. Location first: targeting acute myeloid leukemia within its niche
Herrmann et al. Extracellular vesicles in musculoskeletal pathologies and regeneration
Erdmann et al. IL-17A promotes macrophage effector mechanisms against Trypanosoma cruzi by trapping parasites in the endolysosomal compartment
BRPI0917037A2 (pt) ''molécula de ligação específica uso de uma molécula de ligação específica que ligue ao anx- a1 método para o tratamento da doença mediada com células t
Matsubara et al. CD22-binding synthetic sialosides regulate B lymphocyte proliferation through CD22 ligand-dependent and independent pathways, and enhance antibody production in mice
Puricelli et al. Platelets, protean cells with all-around functions and multifaceted pharmacological applications
R. Jabir et al. Cardiovascular disease management through restrained inflammatory responses
AR042968A1 (es) Anticuerpos de virus anti-dengue composiciones metodos y usos

Legal Events

Date Code Title Description
FC Refusal